Dr Hannah Moody

PhD

Post-Doc Research Associate

Role at Hull York Medical School

Dr Hannah Moody is a Postdoctoral Research Associate with the Centre for Cancer Studies, and has been involved in the basic science of cancer for 5 years.

Dr Moody read her BSc in Biological Sciences at Teesside University, and went on to complete a PhD in Medical Sciences with HYMS.

Her major area of interest is thoracic cancers and the drive to understand why many of these malignancies are resistant to treatment.

Publications
  • Moody HL, Lind MJ, Maher SG (2017) MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma, Molecular Therapy: Nucleic Acids, 8, 317-329.
  • H. Moody, M. Lind, S. Maher (2016) MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma via altered intracellular drug localisation, European Journal of Cancer, Vol. 61, S140.
  • Hannah Moody, Michael Lind, Stephen Maher (2015) BACR 14: MicroRNA-31 mediates chemoresistance in malignant pleural mesothelioma via reduced cisplatin intranuclear accumulation, http://abstracts.ncri.org.uk.
  • H.L. Moody, M.J. Lind, S.G. Maher (2015) MicroRNA-31 expression mediates chemoresistance in malignant pleural mesothelioma, Lung Cancer, Vol. 87, S1–S2.
  • Maher, S., Bibby, B., Moody, H. and Reid, G. (2015) MicroRNA and Cancer, Epigenetic Cancer Therapy, Elsevier.